Use of mesenchymal stem cell therapy in COVID-19 related strokes
Mahika Rawat
Chiao Ng
Emaad Khan
Rayyan A.Shah
Suha Ashfaq
Ghaith A.Bahader
Zahoor A.Shah
Department of Medicinal and Biological Chemistry,College of Pharmacy and Pharmaceutical Sciences,University of Toledo,Toledo,OH,USA
摘要：Coronavirus disease 2019(COVID-19)has affected a broad demographics,eliciting a more significant effect on specific groups such as males,African Americans,and Hispanic minorities.Treatment of COVID-19 often requires antiviral drugs or monoclonal antibodies.However,immunotherapies such as mesenchymal stem cells and mesenchymal stem cells-derived exosomal vesicles should be evaluated as treatment options for COVID-19.Mesenchymal stem cell therapy offers regenerative,anti-inflammatory,and immunomodulatory properties that can speed up the recovery from COVID-19.Mesenchymal stem cell therapy can also benefit COVID-19 patients who suffer from strokes,as COVID-19 increases the risk of strokes due to increased cytokines and clotting factors.Most stroke cases that occur in COVID-19 patients are ischemic strokes.Therefore,with the help of mesenchymal stem cell therapy and mesenchymal stem cells-derived exosomes,COVID-19-induced stroke patients might benefit from dual-ended treatment.The objective of this review was to discuss COVID-19 and stroke incidence and the available treatment options.
机标关键词：covid-19stemcellmesenchymalrelatedstrokestherapy
论文发表日期：2023-09-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：3( 1881-1883 )
英文信息